Gen-Probe to Webcast Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated
(Nasdaq: GPRO) announced today that the Company will present at the Merrill
Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in
New York on February 6, 2007 at approximately 8:40 a.m. Eastern Time
(5:40 a.m. Pacific Time). The presentation is scheduled to be webcast live
and may be accessed through a link on the investor information section of
Gen-Probe's website at www.gen-probe.com. The webcast will be available for
30 days following the event.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture
and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs)
that are used primarily to diagnose human diseases and screen donated human
blood. Gen-Probe has more than 20 years of NAT expertise, and received the
2004 National Medal of Technology, America's highest honor for technological
innovation, for developing NAT assays for blood screening. Gen-Probe is
headquartered in San Diego and employs approximately 1,000 people. For more
information, go to www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance are not
historical facts and are forward-looking statements. Forward-looking
statements are not guarantees of performance. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied by any forward-looking statement. For information about
risks and uncertainties we face and a discussion of our financial statements
and footnotes, see documents we have filed with the SEC, including the Form
10-Q for the quarter ended September 30, 2006, and all subsequent periodic
filings made with the SEC. We assume no obligation and expressly disclaim any
duty to update any forward-looking statement to reflect events or
circumstances after the date of this press release or to reflect the
occurrence of unanticipated events.
Contact:
Paula Izidoro
Investor Relations
858-410-8904
SOURCE Gen-Probe Incorporated
01/30/2007
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,
+1-858-410-8904
Web site: http://www.gen-probe.com
|